Recurrent epithelial ovarian cancer: an update on treatment

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months...

Full description

Saved in:
Bibliographic Details
Published inOncology (Williston Park, N.Y.) Vol. 27; no. 4; p. 288
Main Authors Foley, Olivia W, Rauh-Hain, J Alejandro, del Carmen, Marcela G
Format Journal Article
LanguageEnglish
Published United States Intellisphere, LLC 01.04.2013
MultiMedia Healthcare Inc
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Carcinoma, Ovarian Epithelial
Chemotherapy
Development and progression
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Drug therapy
Female
Guanidines - administration & dosage
Health aspects
Humans
Neoplasm Recurrence, Local - drug therapy
Neoplasms, Glandular and Epithelial - drug therapy
Ovarian cancer
Ovarian Neoplasms - drug therapy
Polyethylene Glycols - therapeutic use
Relapse
Time Factors
United States
Online AccessGet full text

Cover

More Information
Summary:An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Feature-3
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0890-9091